Business Context and Reporting Period
This Form 8-K is a current report filed by Frequency Therapeutics, Inc. (trading symbol: FREQ) on April 11, 2022. The registrant is a Delaware corporation headquartered in Lexington, MA, and is classified as an emerging growth company. The filing primarily addresses executive retention arrangements approved by the Board of Directors.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on specific compensatory arrangements and does not contain a financial statement or performance summary.
Material Changes and Executive Compensation
On April 11, 2022, the Board approved retention bonuses for three executives: David Lucchino (CEO), Richard Mitrano (VP of Finance and Operations), and Wendy Arnold (Chief People Officer). Formal letter agreements were executed on April 15, 2022, for Mr. Mitrano and Ms. Arnold with the following terms:
- Cash Bonuses:
- $75,000 payable upon public disclosure of Phase 2b clinical trial results for FX-322 (FX-322-208).
- $50,000 payable within ten days of completing a bona fide third-party security financing transaction with gross proceeds of at least $25 million on or before December 31, 2023.
- Restricted Stock Units (RSUs):
- Mr. Mitrano and Ms. Arnold: 110,000 shares each.
- Mr. Lucchino: 300,000 shares.
- Vesting Condition: All RSUs vest in full only upon the achievement of the $25 million financing milestone.
- Employment Condition: Cash bonuses are contingent on continued employment through the payment date.
Outlook, Risks, and Contingencies
The filing highlights a critical contingency for the company's liquidity and executive retention: the need to secure at least $25 million in financing by December 31, 2023. Failure to achieve this "Financing Milestone" would result in the forfeiture of the RSUs granted to the executives and the $50,000 cash bonus portion for Mr. Mitrano and Ms. Arnold. Additionally, the company is awaiting the public disclosure of results from its Phase 2b clinical trial for FX-322, which triggers the first cash bonus payment.
Investor Verification Checklist
- Verify the current status of the Phase 2b clinical trial (FX-322-208) and whether results have been publicly disclosed.
- Confirm whether the company has secured the required $25 million financing transaction by the December 31, 2023 deadline.
- Review the full text of the Retention Agreements (Exhibits 10.1 and 10.2) for additional terms not summarized in the 8-K.
- Monitor subsequent filings for updates on the company's cash position and capital raise efforts.